Central administration of an ERα agonist, namely 1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), can enhance the physical interaction between SRC-1 and ERα proteins in mouse hypothalamus, and this interaction is involved in the anti-obesity effects of estrogen in female mice [27]. Here, SRC is linked to obesity disorder.